Usefulness of Longitudinal Measurements of β-Amyloid1–42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders

This publication has 13 references indexed in Scilit:

• Effects of Processing and Storage Conditions on Amyloid β (1–42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice
  Clinical Chemistry, 2005
• Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier‐mediated epitope masking of amyloid β peptides
  Electrophoresis, 2004
• Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease
  Neurology, 2004
• Cerebrospinal fluid markers for prediction of Alzheimer's disease
  Neuroscience Letters, 2003
• CSF markers for incipient Alzheimer's disease
  The Lancet Neurology, 2003
• Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease
  Neuroscience Letters, 2000
• Standardization of measurement of β-amyloid_(1-42)in cerebrospinal fluid and plasma
  Amyloid, 2000
• Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease
  Archives of Neurology, 1999
• Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan
  Annals of Neurology, 1998
• A NOTE ON NORMAL CORRELATION
  Biometrika, 1939